<DOC>
	<DOCNO>NCT00337467</DOCNO>
	<brief_summary>The main purpose explore whether atazanavir/ritonavir ( ATV/RTV ) single enhanced protease inhibitor therapy maintain virologic suppression without marked increase virologic failure .</brief_summary>
	<brief_title>Phase IIIb Study Evaluate Effectiveness Safety Atazanavir/Ritonavir Single Enhanced Protease Inhibitor Therapy Human Immunodeficiency Virus ( HIV ) -Infected Subjects Evidencing Virologic Suppression</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>On continued antiretroviral ( ARV ) treatment , discontinuation period , previous 6 month ( 24 week ) . Absence evidence suspect virologic failure antiretroviral therapy Absence know primary mutation protease gene Only 1 highly active antiretroviral therapy ( HAART ) prior current one HIV RNA &lt; 50 copies/mL last 6 month ( single blip 200 c/mL allow ) On ATV/RTV +2 nucleoside reverse transcriptase inhibitor ( NRTIs ) ( 1 NRTI + tenofovir [ TDF ] ) least 8 week study entry , without treatmentlimiting adverse effect Presence newly diagnose HIVrelated opportunistic infection medical condition require acute therapy time enrollment . Active disease condition ( e.g . moderate severe hepatic impairment/active renal disease/history clinically significant heart conduction disease ) Patients chronic hepatitis B receiving lamivudine ( 3TC ) , Tenofovir Disoproxil Fumarate ( TDF ) emtricitabine ( FTC ) . CD4 &lt; 100 cells/mm3 Grade IV laboratory value : Hemoglobin &lt; 6.5 g/dL white blood cell ( WBC ) &lt; 800/mmm3 absolute neutrophil count &lt; 500/mm3 , platelet &lt; 20,000/mm3 diffuse petechia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>HIV-Infected Patients Evidencing Virologic Suppression</keyword>
</DOC>